New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
15:35 EDTGTY, TRK, TAC, PYA, KMPR, TFX, SXL, PLP, HMN, VRS, TFG, SA, PBYI, BXG, CPK, BBX, CDINYSE says cash equities market experienced issue with matching engine
The NYSE cash equities market has recovered from an issue with one matching engine affecting order processing and trade execution in 26 symbols. Recovery has been completed and all NYSE trading systems are functioning normally, the exchange stated. A list of affected symbols is available via the following link: Reference Link
News For BBX;BXG;CDI;CPK;GTY;HMN;KMPR;PBYI;PLP;PYA;SA;SXL;TAC;TFG;TFX;TRK;VRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2015
08:46 EDTPBYIPuma Biotechnology expands cohort in Phase II PB272 trial
Puma Biotechnology has expanded the second cohort from its Phase II clinical trial of its lead drug candidate PB272 as a single agent in patients with solid tumors who have an activating HER2 mutation. The cohort that has been expanded is the cohort that includes patients with metastatic non-small cell lung cancer and whose tumors have a HER2 mutation. The Phase II basket trial, which was initiated in October 2013, is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating (driver) ERBB mutations, including epidermal growth factor receptor, HER2 and HER3. The cohorts (baskets) included in the study are (1) bladder/urinary tract cancer; (2) breast cancer; (3) colorectal cancer; (4) endometrial cancer; (5) gastric/esophageal cancer; (6) ovarian cancer; (7) all other solid tumors with a HER2 mutation; (8) EGFR mutated and/or amplified primary brain cancer; and (9) solid tumors with a HER3 mutation. The non-small cell lung cancer patients initially entered the study in the “other solid tumors with a HER2 mutation” basket and due to the preliminary activity seen in the trial the Company has expanded the basket, as per the protocol for the trial. The expanded HER2 mutant NSCLC basket will now enroll a total of 18 patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use